Author

Rupal Patel

Observed names: Dr. Rupal M. Patel, Rupal M Patel, Rupal M. Patel

Institutions: Shree Krishna Hospital, Pramukhswami Medical College, Bhaikaka University

Observed institutions: Shree Krishna Hospital, Pramukhswami Medical College, Bhaikaka University

ORCID: 0000-0003-4809-5494

Observed ORCIDs: 0000-0003-4809-5494, 0009-0005-5978-2179

OpenAlex ID: A5104110838

Geriatric Respondents and Non-Respondents to Probiotic Intervention Can be Differentiated by Inherent Gut Microbiome Composition

2015 · Suja Senan, Jashbhai B. Prajapati, et al. · Frontiers in Microbiology · 29

Effect of Probiotic Dietary Intervention on Calcium and Haematological Parameters in Geriatrics

2016 · Manisha Kalpesh Gohel, Jashbhai B Prajapati, et al. · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · 16

Incidence density rate of multidrug-resistant organism (MDRO) at a tertiary care teaching hospital: A retrospective cross-sectional study

2024 · Rupal Patel, Pinal Joshi, et al. · Indian Journal of Microbiology Research · 4

An Approach to Track and Analyze the Trend of Antimicrobial Resistance Using Python: A Pilot Study for Anand, Gujarat, India—May 2022–August 2023

2023 · Priyanshu Khound, Himanshu Pandya, et al. · Microbial Drug Resistance · 1

Diagnostic accuracy of the RESIST-5 O.K.N.V.I. immunochromatographic assay for detection of carbapenemase-producing Gram-negative bacteria: comparison with real-time PCR

2026 · Jainikkumar Patel, Avani Raulji, et al. · Diagnostic Microbiology and Infectious Disease

Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli

2026 · Siddhi A. Darji, Avani Raulji, et al. · The Journal of Antibiotics

Supplementary Data 2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

2026 · Melissa R. Junttila, Claire E. Repellin, et al.

Supplementary Table S1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

2026 · Melissa R. Junttila, Claire E. Repellin, et al.

Data from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations

2026 · Melissa R. Junttila, Claire E. Repellin, et al.

Anti-fungal Consumption by Days of Therapy (DOT) Metric in a Teaching Hospital: A Step towards Anti-fungal Stewardship

2024 · Rupal Patel, Binal Chauhan, et al. · Journal of Antimicrobial Stewardship Practices and Infectious diseases

Supplementary Figures 1 - 2 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

2023 · Alexander Drilon, Salvatore Siena, et al.

Supplementary Tables 1-6 from Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

2023 · Alexander Drilon, Salvatore Siena, et al.

Supplementary figures 1-2 from Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

2023 · Gang G. Li, Romel Somwar, et al.

Supplementary figure legends from Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

2023 · Gang G. Li, Romel Somwar, et al.

Data from Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

2023 · Gang G. Li, Romel Somwar, et al.

Nonfermenting Gram-negative bacilli other than Pseudomonas aeruginosa and Acinetobacter baumanii infections at a tertiary care teaching hospital in Gujarat.

2021 · Pinal Joshi, Dr. Rupal M. Patel, et al. · Indian Journal of Medical Microbiology

Works count: 16

Citation count: 50

H-index: 3

I10-index: 2